
BDTX Stock Forecast & Price Target
BDTX Analyst Ratings
Bulls say
Black Diamond Therapeutics Inc. is positioned for significant growth due to its advanced pipeline, particularly with the expected clinical trial results for their therapies, BDTX-4933 and BDTX-1535, which are anticipated to create value inflection points that could elevate their stock value substantially. The company is projected to achieve forecasted sales of approximately $500-750 million if they secure a good Overall Response Rate (ORR) in late 2025, enhancing their attractiveness for potential mergers and acquisitions by leveraging similar-sized oncology market valuations. Additionally, the strong clinical performance of silevertinib, exhibiting a 60% confirmed Overall Response Rate (cORR) across a broad spectrum of patients, reinforces the company's capabilities in targeting actionable mutations—indicating a lucrative opportunity in the first-line non-small cell lung cancer market, projected to exceed $1 billion.
Bears say
Black Diamond Therapeutics Inc. is facing significant challenges regarding the confidence in its clinical pipeline, particularly concerning the performance of its drug, silevertinib, which has shown lower confirmatory objective response rates (cORR) compared to competitors in relevant clinical settings. Additionally, the company's overall market capitalization of approximately $230 million suggests a lack of investor confidence, exacerbated by concerns over the drug's efficacy in a broader patient population and the impact of lowered dosing on treatment effectiveness. Overall, uncertainties related to the drug's competitiveness and efficacy diminish Black Diamond’s financial outlook, indicating potential struggles in gaining traction in the oncology market.
This aggregate rating is based on analysts' research of Black Diamond Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
BDTX Analyst Forecast & Price Prediction
Start investing in BDTX
Order type
Buy in
Order amount
Est. shares
0 shares